Felix Sedlmayer
Overview
Explore the profile of Felix Sedlmayer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1698
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roeder F, Fastner G, Fussl C, Sedlmayer F, Stana M, Berchtold J, et al.
Radiat Oncol
. 2023 Nov;
18(1):186.
PMID: 37950314
Intraoperative radiation therapy (IORT) is a radiation technique applying a single fraction with a high dose during surgery. We report the first abdomino-pelvic application of an image-guided intraoperative electron radiation...
2.
Berchtold J, Winkler C, Karner J, Groher M, Gaisberger C, Sedlmayer F, et al.
Strahlenther Onkol
. 2023 Aug;
200(3):195-201.
PMID: 37626226
Purpose: In ultrahypofractionated radiation concepts, managing of intrafractional motion is mandatory because tighter margins are used and random errors resulting from prostate movement are not averaged out over a large...
3.
Grambozov B, Kalantari F, Beheshti M, Stana M, Karner J, Ruznic E, et al.
Radiother Oncol
. 2023 Jun;
185:109728.
PMID: 37301259
Background And Purpose: Our study aimed to assess whether quantitative pretreatment 18F-FDG-PET/CT parameters could predict prognostic clinical outcome of recurrent NSCLC patients who may benefit from ablative reirradiation. Materials And...
4.
Stana M, Grambozov B, Karner J, Gollner I, Gaisberger C, Ruznic E, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046627
Introduction: Durvalumab following chemoradiotherapy (CRT) for non-small cell lung cancer stage III has become the standard of care (SoC) in the past few years. With this regimen, 5-year overall survival...
5.
Roeder F, Gerum S, Hecht S, Huemer F, Jager T, Kaufmann R, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428801
Total neoadjuvant therapy (TNT)-the neoadjuvant employment of radiotherapy (RT) or chemoradiation (CRT) as well as chemotherapy (CHT) before surgery-may lead to increased pathological complete response (pCR) rates as well as...
6.
Wass R, Hochmair M, Kaiser B, Grambozov B, Feurstein P, Weiss G, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804997
Introduction: The standard of care (SoC) for unresectable stage III non-small-cell lung cancer (NSCLC) is durvalumab maintenance therapy after concurrent chemoradiation in patients with PD-L1 > 1%. However, the concurrent...
7.
Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases
Muller A, Aebersold D, Albrecht C, Bohmer D, Flentje M, Ganswindt U, et al.
Strahlenther Onkol
. 2022 Jun;
198(8):683-689.
PMID: 35704054
Purpose: The DEGRO Expert Commission on Prostate Cancer has revised the indication for radiation therapy of the primary prostate tumor in patients with synchronous distant metastases with low metastatic burden....
8.
Stana M, Grambozov B, Gaisberger C, Karner J, Ruznic E, Berchtold J, et al.
Diagnostics (Basel)
. 2022 May;
12(5).
PMID: 35626183
Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to...
9.
Piroth M, Krug D, Feyer P, Baumann R, Combs S, Duma M, et al.
Strahlenther Onkol
. 2022 May;
198(7):601-611.
PMID: 35527272
Evidence from a few small randomized trials and retrospective cohorts mostly including various tumor entities indicates a prolongation of disease free survival (DFS) and overall survival (OS) from local ablative...
10.
Piroth M, Strnad V, Krug D, Fastner G, Baumann R, Combs S, et al.
Breast Care (Basel)
. 2022 Mar;
17(1):81-84.
PMID: 35355706
Background: During the last decade, partial breast irradiation (PBI) has gained traction as a relevant treatment option for patients with early-stage low-risk breast cancer after breast-conserving surgery. The TARGIT-A prospective...